652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC)
Arbour K, Punekar S, Garrido-Laguna I, Hong D, Wolpin B, Pelster M, Barve M, Starodub A, Sommerhalder D, Chang S, Zhang Y, Salman Z, Wang X, Gustafson C, Spira A. 652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Annals Of Oncology 2023, 34: s458. DOI: 10.1016/j.annonc.2023.09.1838.Peer-Reviewed Original Research